| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.029 | 0.3 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.033 | 0.4 |